November 19, 2020
1 min read
Save
SENECA
Issue: November 2020
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Safety and feasibility of stem cells in patients who survived cancer with left ventricular dysfunction secondary to cardiomyopathy from anthracycline.